跳转至内容
Merck
CN
  • Cold-inducible RNA-binding protein mediates neuroinflammation in cerebral ischemia.

Cold-inducible RNA-binding protein mediates neuroinflammation in cerebral ischemia.

Biochimica et biophysica acta (2014-03-13)
Mian Zhou, Weng-Lang Yang, Youxin Ji, Xiaoling Qiang, Ping Wang
摘要

Neuroinflammation is a key cascade after cerebral ischemia. Excessive production of proinflammatory mediators in ischemia exacerbates brain injury. Cold-inducible RNA-binding protein (CIRP) is a newly discovered proinflammatory mediator that can be released into the circulation during hemorrhage or septic shock. Here, we examine the involvement of CIRP in brain injury during ischemic stroke. Stroke was induced by middle cerebral artery occlusion (MCAO). In vitro hypoxia was conducted in a hypoxia chamber containing 1% oxygen. CIRP and tumor necrosis factor-α (TNF-α) levels were assessed by RT-PCR and Western blot analysis. CIRP is elevated along with an upregulation of TNF-α expression in mouse brain after MCAO. In CIRP-deficient mice, the brain infarct volume, induction of TNF-α, and activation of microglia are markedly reduced after MCAO. Using microglial BV2 cells, we demonstrate that hypoxia induces the expression, translocation, and release of CIRP, which is associated with an increase of TNF-α levels. Addition of recombinant murine (rm) CIRP directly induces TNF-α release from BV2 cells and such induction is inhibited by neutralizing antisera to CIRP. Moreover, rmCIRP activates the NF-κB signaling pathway in BV2 cells. The conditioned medium from BV2 cells exposed to hypoxia triggers the apoptotic cascade by increasing caspase activity and decreasing Bcl-2 expression in neural SH-SY5Y cells, which is inhibited by antisera to CIRP. Extracellular CIRP is a detrimental factor in stimulating inflammation to cause neuronal damage in cerebral ischemia. Development of an anti-CIRP therapy may benefit patients with brain ischemia.

材料
货号
品牌
产品描述

Sigma-Aldrich
无水柠檬酸粉末, meets analytical specification of Ph. Eur., BP, USP, E330, anhydrous, 99.5-100.5% (based on anhydrous substance)
Sigma-Aldrich
无水柠檬酸粉末, ACS reagent, ≥99.5%
Sigma-Aldrich
三氯乙酸 溶液, 6.1 N
Sigma-Aldrich
2-二(2-羟乙基)氨基-2-羟甲基-1,3-丙二醇, ≥98.0% (titration)
Sigma-Aldrich
三氯乙酸, ACS reagent, ≥99.0%
Sigma-Aldrich
无水柠檬酸粉末, 99%
SAFC
2-二(2-羟乙基)氨基-2-羟甲基-1,3-丙二醇
Sigma-Aldrich
无水柠檬酸粉末, ≥99.5%, FCC, FG
Sigma-Aldrich
无水柠檬酸粉末, anhydrous, suitable for cell culture, suitable for plant cell culture
USP
无水柠檬酸粉末, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
2-二(2-羟乙基)氨基-2-羟甲基-1,3-丙二醇, BioUltra, ≥99.0% (NT)
Sigma-Aldrich
无水柠檬酸粉末, BioUltra, anhydrous, ≥99.5% (T)
Supelco
柠檬酸, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
2-二(2-羟乙基)氨基-2-羟甲基-1,3-丙二醇, BioXtra, ≥98.0% (titration)
Sigma-Aldrich
三氯乙酸, suitable for electrophoresis, suitable for fixing solution (for IEF and PAGE gels), ≥99%
Sigma-Aldrich
2-二(2-羟乙基)氨基-2-羟甲基-1,3-丙二醇, BioPerformance Certified, suitable for cell culture, suitable for insect cell culture, ≥98.0%
Sigma-Aldrich
三氯乙酸, BioUltra, ≥99.5% (T)
Sigma-Aldrich
无水柠檬酸粉末, anhydrous, free-flowing, Redi-Dri, ACS reagent, ≥99.5%
Sigma-Aldrich
三氯乙酸, ≥99.0% (titration)
Sigma-Aldrich
三氯乙酸, BioXtra, ≥99.0%
Sigma-Aldrich
2-羟基丁酸 钠盐, 97%
SAFC
2-二(2-羟乙基)氨基-2-羟甲基-1,3-丙二醇
Sigma-Aldrich
三氯乙酸, ACS reagent, for the determination of Fe in blood according to Heilmeyer, ≥99.5%
Supelco
无水柠檬酸粉末, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
无水柠檬酸粉末, anhydrous, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
无水柠檬酸粉末, Vetec, reagent grade, 99%
Sigma-Aldrich
2-二(2-羟乙基)氨基-2-羟甲基-1,3-丙二醇, Vetec, reagent grade, ≥98%, RNase and DNase free